Exercise in Juvenile Takayasu Disease
- Conditions
- Takayasu's Arteritis
- Interventions
- Behavioral: Exercise
- Registration Number
- NCT03494062
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
Juvenile Takayasu disease is characterized by chronic inflammation that leads to vascular disease. Exercise may render anti-inflammatory effects and protect against cardiovascular events. This trial aims to investigate the therapeutic role of exercise in juvenile Takayasu disease.
- Detailed Description
Takayasu's Arteritis (TA) is a chronic inflammatory disease that affects large and medium-sized arteries. The number of cases describe in children and adolescents has growing, and the hypertension is one of the symptoms most common, followed by other manifestations that affects cardiovascular systems. All clinical manifestations may aggravate by physical inactivity and can creating a vicious cycle of inflammation, whereas the risks of morbidity and mortality increase significantly in the pediatric population, impairing function and physical capacity, quality of life and evolution to adult life. Thereby, physical exercise it is show to be an efficient strategy to reduce all these risk factors, however, no one study, until now, was conducted to available the effects of exercise in children with TA. Objective: Investigated the effects of 12-week home-based exercise program, where the patients receive a guideline from a physical education professional, teaching how to do the exercise at home. The beneficial effects of the programs expect is to be associated with improved cardiovascular risk factors, function and physical capacity, and body composition. Methods: This is a prospective, longitudinal and randomized clinical trial. All patients will be recruited at the Clinical Hospital of the University of Sao Paulo Medical School (HC-FMUSP), in the Laboratory of Evaluation and Conditioning in Rheumatology, Pediatric Rheumatology outpatient clinics of the Department of Pediatrics, Federal University of São Paulo and The Children's Institute of the University of São Paulo and the Vasculitis Unit of the HC-FMUSP Rheumatology Service. In order to evaluate the therapeutic effects of exercise program act on TA, the following pre and post intervention evaluations will be performed: physical activity level; Global clinical evaluation; Anthropometry and body composition; Hematological and inflammatory blood parameters; Cardiovascular risk factors; Aerobic capacity; Functional capacity and fatigue; quality of life; and 18 FDG PET with magnetic resonance angiography.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 21
- diagnosis of juvenile Takayasu disease
- cardiac and renal insufficiency
- physical limitation hampering exercise training
- non-controlled metabolic disorders
- associated chronic diseases (last 6 months)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Exercise Exercise Home-based exercise intervention
- Primary Outcome Measures
Name Time Method Blood inflammatory marker 12 weeks C-reactive protein
Arterial inflammation 12 weeks as assessed by positron emission tomography - magnetic ressonance (PET-MR)
Blood inflammatory markers 12 weeks interleukin-6, interleukin 10, interleukin-12
velocity sedimentation rate 12 weeks velocity sedimentation rate
- Secondary Outcome Measures
Name Time Method Timed stands test 12 weeks The test is performed by measuring the time to stand up and down for 30 seconds. The patient should make two attempts and the best performance will be considered for the analyzes.
Isometric strength 12 weeks handgrip test
Maximal strength test 12 weeks will be performed by the maximum repetition test, where the objective is to find a maximal repetition for lower limbs by leg press exercise 45º and for upper limbs by bench press exercise
Maximal aerobic capacity 12 weeks as assessed by maximal cardiopulmonary test
Body composition 12 weeks Lean, fat and bone mass, as assessed by dual energy x-ray absorptiometry
Fatigue severity scale FSS 12 weeks The Fatigue severity scale will be used to monitor the change in fatigue in response to the intervention. For each item, you must tick from 1 totally disagree to 7 agree totally. The total number of points may vary from 9 to 63, and it is established that values equal to or greater than 28 are indicative of the presence of fatigue
timed-up-and-go test 12 weeks The "Timed Up-And-Go" test, which evaluates the time it takes for the patient to get up from a chair, walk three meters, make a 180-degree turn, and return to the chair. The patient should perform two attempts and the best performance will be considered for the analyzes.
Childhood Health Assessment Questionaire (CHAQ) 12 weeks The Childhood Health Assessment Questionnaire (CHAQ) is a disease specific health instrument that measures functional ability in daily living activities in children
Physical activity levels 12 weeks The level of physical activity of patients will be measured using the Actigraph GT3x® triaxial accelerometer (Actigraph®).
Quality of life 12 weeks as assessed by Short-Form-36
Hypotension after acute exercise session 12 weeks after maximal aerobic capacity, the blood pressure will be will be measured in the four limbs, both arms and legs, every fifteen minutes, for an hour.
The Paediatric Vasculitis Activity Score (PVAS) 12 weeks The final PVAS is a clinical index of 64 manifestations of active vasculitis, divided into five domains: general, cutaneous, cardiovascular, abdominal and renal.
Indian Takayasu's Arteritis Activity Score 2010 (ITAS2010 12 weeks ITAS2010 contains 44 items with 33 features arising from the cardiovascular system. Seven key items are weighted to score 2 and all others score 1 only.
National Institute of Health (NIH) 12 weeks The NIH criteria is an instrument that will evalueted the disease specific symptoms and his activity. Active disease will arbitrarily defined as new onset or worsening of at least 2 of the following 4 features: (I) signs and symptoms of vascular ischemia or inflammation (e.g. claudication, decreased or absent extremity pulses or blood pressure, bruits, or carotidynia); (2) elevated erythrocyte sedimentation rate; (3) angiographic abnormalities; and (4) systemic symptoms not attributable to another disease.
Trial Locations
- Locations (1)
University of Sao Paulo
🇧🇷São Paulo, Castanho, Brazil